Bilateral injections are billed with a -50 modifier per payer guidelines
Amin A, Hossen MJ, Fu XQ, Chou JY, Wu JY, Wang XQ, et al
I don't know where I got that from
10.1113/jp275230 44 SeferovicM
For Sparks, we applied the same criteria weve used in most of those other articles, looking closely at efficacy and safety but also comparing costs to other products
Funding for CLSA is provided by the Government of Canada through the Canadian Institutes of Health Research (CIHR) under grant reference: LSA 94473 and the Canada Foundation for Innovation, as well as the following provinces, Newfoundland, Nova Scotia, Quebec, Ontario, Manitoba, Alberta, and British Columbia